Participating and Non-Participating Payers
AVAP is pleased to report that the vast majority of payers with beneficiaries in Alaska are participating in AVAP for 2017.
The following payers are not participating for 2017:
3. Prudential Insurance Company of America
2017 State-supplied Vaccines
2017 Adult Eligibility Requirements
2017 Child Eligibility Requirements
Provider Payment Policy
Provider Opt in
What is provider opt in?
In order to opt in, providers pay an assessment for their uninsured adult population served. Providers who opt in can then receive select state-supplied vaccines for their uninsured adult population ONLY.
In 2017, the provider opt in will not permit giving state-supplied vaccines to an adult that is insured by a non-participating or opt out payer. Therefore, an adult with Medicare, Medicaid, TRICARE or Prudential Insurance Company of America will need to be given private vaccine.
What is the assessment rate?
The 2017 assessment rate is $0.60 per adult per month (or $7.20 per adult per year). You will be invoiced annually based on the total number of uninsured adults you report. For example, if you report 100 uninsured adults, you will be invoiced $720 ($0.60/adult/month x 100 uninsured adults x 12 months).
How do I determine the total number of uninsured adults?
To determine the number of uninsured adults by facility, query your electronic health record (EHR) system or billing system for the total number of adults aged 19 years and older without a third party payer (like private insurance, Medicaid, or Medicare) seen in the last year.
Is there a minimum quarterly assessment amount I must pay?
Providers must pay for a minimum of 50 uninsured adults. If you serve less than 50 uninsured adults, you will report a total of 50 uninsured adults. For example, if you serve 20 uninsured adults, you will report 50 uninsured adults and be invoiced $360 ($0.60/adult/month x 50 uninsured adults x 12 months).
What are the 2017 select state-supplied vaccines for adults?
|Adult Vaccines||Brand Name®||Age Criteria (in years)|
|9vHPV (Human papillomavirus)||Gardasil 9||Females 19 through 26; males 19 through 21; high risk* males 22 through 26|
|9vHPV (Human papillomavirus)||Varies each season||19+|
|MCV4 (Meningococcal conjugate)||Menactra||19 through 20|
|MenB (Meningococcal B)**||Bexsero||19 through 20|
|PPSV23 (Pneumococcal polysaccharide)||Pneumovax 23||19+|
|Td (Tetanus/ Diphtheria)||Tenivac||19+|
|Tdap (Tetanus/ Diphtheria/ acellular Pertussis)||BOOSTRIX||19+|
|Zoster (shingles)||Zostavax||60 through 24|
*High risk males include either men who have sex with men (MSM) or who have an immunocompromising condition.
** Limited availability for high risk groups, which include those with persistent complement component deficiencies, anatomic or functional asplenia, microbiologist routinely exposed to isolates of Neisseria meningitidis, and populations at risk because of a serogroup B meningococcal disease outbreaks.